E-Learning Center
Join Our Network
OncoFacts

Follow Imedex on Twitter

Register for an upcoming conference!

Phone: +1 (678) 242 0906
registration@imedex.com

Lymphoma and Myeloma 2009: An International Congress on Hematologic Malignancies


Register Now

Lymphoma and Myeloma 2009: An International Congress on Hematologic Malignancies

October 22-24, 2009

New York, New York

Waldorf=Astoria

Continuing Medical Education

CME Statement
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 18.5 of AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Who Should Attend

This educational activity is specifically designed for hematologists, medical oncologists, transplant oncologists, radiation oncologists and other physicians, physicians-in-training, and healthcare professionals (nurses, pharmacists) involved in and/or interested in lymphoma, myeloma and related plasma cell disorders and their management.

Objectives

After attending this Congress, participants should be able to:

  • Discuss insights into the biology of CLL
  • Discuss evidenced-based approaches to therapy in CLL in both the frontline and relapsed setting
  • Review experimental and recently approved agents in CLL
  • Review the most up to date clinical trial data in lymphoplasmocytic disorders
  • Discuss the new WHO classification of lymphoma
  • Comment on the evolution and future of treatment for Hodgkin’s disease
  • Review the optimal frontline strategy for patients with peripheral T cell lymphoma
  • Discuss progress made in cutaneous T cell lymphoma
  • Debate the aggressive treatment of mantle cell lymphoma
  • Improve prevention and treatment of central nervous system lymphoma
  • Comment on the role of epigenetic targeting of large cell lymphoma
  • Utilize prognostic factors to optimize treatment of low grade lymphoma
  • Review treatment of lymphomas of the eye
  • Discuss utility and safety of novel agents in low grade lymphoma
  • Debate the role of PET scans in Hodgkin’s and NHL
  • Review updates in myeloma biology, including cell trafficking, mobilization and targeting the cell cycle
  • Review the evaluation of minimal residual disease in myeloma as well as the IMW consensus on response criteria
  • Discuss the current state of the art in targeted therapy for myeloma
  • Review evidence-based treatment options for poor risk and non-transplant eligible patients in the frontline
  • Discuss evidence-based treatment options for consolidation in patients with good prognostic indicators
  • Review novel combination therapies for the treatment of relapsed/refractory myeloma
  • Review highlights from the 2009 International Myeloma Workshop

James R. Berenson, MD
Institute for Myeloma and Bone Cancer Research
West Hollywood, California

Steven Bernstein, MD
University of Rochester Medical Center
Rochester, New York

Joan Bladé, MD
University of Barcelona Hospital Clinic
Barcelona, Spain

Arthur R. Bradwell, MD
University of Birmingham
Birmingham, United Kingdom

John C. Byrd, MD
Ohio State University
Columbus, Ohio

Asher Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, New York

Selina Chen-Kiang, PhD
Weill Medical College of Cornell University
New York, New York

Bruce D. Cheson, MD
Georgetown University Hospital
Washington, District of Columbia

Bertrand Coiffier, MD
Hospices Civils de Lyon
Lyon, France

Morton, Coleman, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York

Raymond L. Comenzo, MD
Tufts University Medical Center
Boston, Massachusetts

Claire Dearden, BSc, M.D., FRCP, FPCPath
Royal Marsden Hospital
Sutton, United Kingdom

Volker Diehl, MD
University Hospital of Cologne
Cologne, Germany

Angela Dispenzieri, MD
Mayo Clinic College of Medicine
Rochester, Minnesota

Rebecca Elstrom, MD
Weill Cornell Medical College
New York, New York

Scott Ely, MD, MPH
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York

Rafael Fonseca, MD
Mayo Clinic
Scottsdale, Arizona

Richard R. Furman, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York

Randy D. Gascoyne, MD
British Columbia Cancer Agency
Vancouver, British Columbia, Canada

Philip R. Greipp, MD
Mayo Clinic
Rochester, Minnesota

Thomas Habermann, MD
Mayo Clinic
Rochester, Minnesota

Jean-Luc Harousseau, MD
Hoteldieu Hospital
Nantes, France

Sandra J. Horning, MD
Stanford University Medical Center
Stanford, California

Steven Horwitz, MD
Memor Sloan-Kettering Cancer Center
New York, New York

Carol Ann Huff, MD
Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Martin Hutchings, MD
Copenhagen University Hospital
Copenhagen, Denmark

Sundar Jagannath, MD
St. Vincent’s Comprehensive Cancer Center
New York, New York

Brad Kahl, MD
University of Wisconsin Carbone
Comprehensive Cancer Center
Madison, Wisconsin

Neil Kaye, MD
Mayo Clinic
Rochester, Minnesota

Eva Kimby, MD, PhD
Karolinska Institute at Huddinge
University Hospital
Stockholm, Sweden

Suzanne Lentzsch, MD, PhD
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

John P. Leonard, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York

Sagar Lonial, MD
Emory University
Atlanta, Georgia

Tomer Mark, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York

Peter Martin, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York

Peter McLaughlin, MD
University of Texas M.D. Anderson Cancer Center
Houston, Texas

Ari Melnick, MD
Albert Einstein College of Medicine
Bronx, New York

Ruben Niesvizky, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York

Antonio Palumbo, MD
University of Torino
Torino, Italy

Roger Pearse, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York

Kanti Rai, MD
Long Island Jewish Medical Center
Albert Einstein College of Medicine
New Hyde Park, New York

S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, Minnesota

Steven Rosen, MD
Robert H Lurie Comprehensive Cancer Center
Chicago, Illinois

Stephen Schuster, MD
University of Pennsylvania
Philadelphia, Pennsylvania

Keith Stewart, M.B.Ch.B
Mayo Clinic
Scottsdale, Arizona

Wayne Tam, MD, PhD
Weill Cornell Medical Center
New York, New York

David J. Wolf, MD
Weill Cornell Medical College
New York, New York

Thursday
October 22, 2009

8:00 am
Welcome
Morton Coleman, MD

 

CLL Section

8:05 am
Introduction
Richard R. Furman, MD

Session I: Biology of CLL
Moderator: John C. Byrd, MD

8:10 am
New insights into CLL biology
Speaker invited

8:30 am
CLL genomics and epigenetics:
What’s on the horizon for clinicians?
John C. Byrd, MD

8:50 am
How do we make sense of prognostic markers in CLL when treating patients?
Kanti Rai, MD

9:10 am
Panel discussion questions

9:30 am
Break

Session II: Treatment of CLL
Moderator: Richard Furman, MD

9:50 am
Evidence-based approaches for treatment-naïve patients
Neil Kaye, MD

10:10 am
Evidence-based approaches for treating relapsed/refractory patients
Claire Dearden, BSc, MD, FRCP, FPCPath

10:30 am
Latest results with IMiDS compounds in CLL:
How do we manage the rash and flare?
Asher Chanan-Khan, MD

10:50 am
Experimental and recently approved novel agents in CLL
Richard R. Furman, MD

11:10 am
Panel discussion

11:20 am
Presentation of the best CLL abstract

11:30 am
Luncheon Symposium

Session III: Lymphoplasmocytic disorders
Moderator: David J. Wolf, MD

1:30 pm
Waldenstrom’s macroglobulinemia: An update
Eva Kimby, MD, PhD

1:50 pm
POEMS and Castleman’s disease: Is there a role for novel agents?
Angela Dispenzieri, MD

2:10 pm
Amyloidosis: Recent data
Raymond L. Comenzo, MD

2:30 pm
Break

 

Lyphoma Section

2:50 pm
Introduction
John P. Leonard, MD

Session IV: Biology of lymphoma
Moderator: Wayne Tam, MD, PhD

2:55 pm
The biologic and pathologic basis for the new WHO classification
Randy D. Gascoyne, MD

3:15 pm
A clinician’s view of the new WHO classification
Speaker invited

3:35 pm
Panel discussion

3:45 pm
Presentation of the best Lymphoma abstract

3:55 pm
The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the
SASS Foundation
Presentation: John Ultmann Award for Contributions to Lymphoma Research
Recipient: Volker Diehl, MD
Presenter: Speaker invited

4:05 pm
Hodgkin’s disease: The past, the present and the future
Volker Diehl, MD

4:35 pm
Questions and answers

4:45 pm
Adjourn

Friday
October 23, 2009

8:00 am
Welcome
Morton Coleman, MD

8:05 am
Introduction
John P. Leonard, MD

Session V: T cell lymphoma
Moderator: Rebecca Elstrom, MD

8:10 am
What is the best front line strategy for peripheral T-cell
lymphoma: Is there a role of novel agents and transplantation?
Steven Horwitz, MD

8:30 am
Have we made progress in the systemic therapy of treating cutaneous T-cell lymphoma?
Steven Rosen, MD

8:50 am
Angioimmunoblastic lymphadenopathy: What is latest in biology and treatment?
Rebecca Elstrom, MD

9:10 am
Panel discussion and questions

9:20 am
Break

Session VI: Mantle cell lymphoma
Moderator: John P. Leonard, MD

9:40 am
Debate: Should mantle cell lymphoma be treated aggressively from the onset?
Pro: Brad Kahl, MD
Con: Peter Martin, MD
Moderator: John P. Leonard, MD

10:20 am
Discussion and questions

Session VII: Special concerns in large cell lymphoma
Moderator: Thomas Habermann, MD

10:30 am
What is the best treat for low stage aggressive lymphomas?
Thomas Habermann, MD

10:50 am
How to prevent and treatment central nervous system disease
Steven Bernstein, MD

11:10 am
How can we improve on large cell lymphoma treatment?
Bertrand Coiffier, MD

11:30 pm
Genomic/epigenetic targeting of large cell lymphoma: Does it have clinical application?
Ari Melnick, MD

11:50 pm
Discussion and questions

12:00 pm
Luncheon Symposium

Session VIII: Low grade lymphoma
Moderator: Peter McLaughlin, MD

2:00 pm
Is follicular lymphoma curable? If not, has it become a chronic illness?
Peter McLaughlin, MD

2:20 pm
Strategies for low grade lymphoma: How to use prognostic indicators in treatment
John P. Leonard, MD

2:40 pm
Lymphomas of the eye: MALT, follicular, large cell
Morton Coleman, MD

3:00 pm
Novel agents in low grade lymphoma: More than we can handle?
Bruce D. Cheson, MD

3:20 pm
Vaccines redux: Useless or a phoenix?
Stephen Schuster, MD

3:40 pm
Break

Session IX: Hodgkin’s disease:PET scanning
Moderator: Morton Coleman, MD

4:00 pm
Point – Counterpoint: PET scans in Hodgkin’s and non-Hodgkin’s lymphoma

The new promise of PET scans
Martin Hutchings, MD, PhD

The new peril of PET scans
Sandra J. Horning, MD

Moderator: Morton Coleman, MD

4:30 pm
Discussion and questions

4:45 pm
Adjourn

Saturday
October 24, 2009

Myeloma Section

8:05 am
Introduction
Ruben Niesvizky, MD

Session X: Biology of myeloma
Moderator: Scott Ely, MD, MPH

8:10 am
Chromosomes, genomics and proteomics as a disease primer: Is M-SMART smart?
Rafael Fonseca, MD

8:30 am
Myeloma cell trafficking and mobilization
Speaker invited

8:50 am
Debate: Does the myeloma stem cell exist? Can we target it for therapeutic purposes?
Suzanne Lentzsch, MD, PhD
Carol Ann Huff, MD

9:20 am
Targeting the cell cycle in myeloma and lymphoma
Selina Chen- Kiang, PhD

9:40 am
Discussion and questions

Session XI: Clinical pathology and myeloma
Moderator: Tomer Mark, MD

9:50 am
Measurement of free light and heavy chains: Applications?
Arthur R. Bradwell, MD

10:05 am
Minimal residual disease in myeloma: Flow cytometry and molecular techniques: Is MRD clinically relevant?
Speaker invited

10:25 am
The Tower of Babel: Multiple response criteria and the need for a unified standard.
Summary of the IMW consensus on response criteria and relevant outcomes
S. Vincent Rajkumar, MD

10:45 am
Break

11:05 am
The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the SASS Foundation
Presentation: Joseph Michaeli Award for Contributions to Myeloma Research
Recipient: Phillip R. Greipp, MD
Presenter: Rafael Fonseca, MD

11:15 am
Sass Foundation/ Michaeli Award Lecture Kinetics, proliferation, and novel agents in myeloma:
Is autologous transplantation an anachronism?
Philip R. Greipp, MD

11:45 pm
Presentation of the best Myeloma abstract

11:55 pm
Special lecture: Targeted therapy in myeloma
Keith Stewart, M.B.Ch.B

12:20 pm
Questions

12:25 pm
Luncheon Symposium

Session XII: Clinical cases and debates in myeloma
Moderator: Ruben Niesvizky, MD

2:15 pm
FIRST LINE THERAPY: Clinical case of poor risk patient
Debate: Sequential therapy vs.combination therapy, triplets or more
Jean-Luc Harousseau, MD (sequential)
Sagar Lonial, MD (combination)

2:45 pm
CONSOLIDATION: Clinical case of good risk patient

Debate: Transplant vs. no transplant
Speaker invited (transplant)
Joan Bladée, MD (no transplant)

3:15 pm
FIRST LINE THERAPY: Clinical case of non-transplant candidate
Debate: bortezomib based vs. IMiD based
Ruben Niesvizky, MD (bortezomib-based)
Antonio Palumbo, MD (IMiD-based)

Session XIII: Relapse/refractory disease
Moderator: Roger Pearse, MD

3:45 pm
SECOND LINE THERAPY: Novel combination therapies for the treatment of relapsed/
refractory multiple myeloma: Current phase I/II combinations using IMiD compounds
and proteasome inhibitors as the backbone
James R. Berenson, MD

4:05 pm
Questions

Session XIV: Special lecture
Moderator: Morton Coleman, MD, FACP

4:10 pm
Highlights from the 2009 International Myeloma Workshop: Are we nearing a cure
in myeloma?
Sundar Jagganath, MD

4:40 pm
Questions

4:50 pm
Adjourn

sumbit abstracts now

 

Participants interested in presenting data should submit abstracts online at www.imedex.com by Thursday, August 20, 2009. Abstracts are subject to acceptance by the Scientific Committee. Once accepted, abstracts will be published in the final Summary Book and scheduled for oral or poster presentation.

Acceptance notifications and guidelines for poster presentation will be sent on Friday, September 25, 2009. Authors of accepted abstracts who have not registered will have until Thursday, October 8, 2009 to do so at the rate of $395.00. After this date, abstracts without registered presenters will be disregarded. Submit your abstract online at www.imedex.com.

Abstract Guidelines

  • Follow the online instructions
  • Abstracts must be written in English
  • Accepted format: Word document format, 9 point Arial font, 500 word count limit
  • Use a concise title
  • List affiliations of author(s) as briefly as possible, with city, state and country
  • Place an asterisk (*) before the name of the presenting author
  • Use standard and well-accepted abbreviations
  • When using references, use standard and well-accepted formats
  • Abstract content should be single-spaced, typed in lower case and contain:
    • Purpose of the study
    • Summarized description of the project
    • Results and conclusions

Submission Deadline
Thursday August 20, 2009

Register Now

 

 

Discounted (Physicians) $395.........................................................(Pharmacists)* $295
If payment received by August 20, 2009

Regular (Physicians) $495................................................................(Pharmacists)* $345
If payment received by October 15, 2009

Full/Onsite (Physicians) $595..........................................................(Pharmacists)* $395
To register after October 15, 2009

Nurses/Residents/Students*........................................................$99
*proof of eligibility must accompany registration

 

The Registration and Information Desk will be staffed:
Thursday, October 22, 2009: 7:00 am – 4:30 pm
Friday, October 23, 2009: 7:30 am – 4:30 pm
Saturday, October 24, 2009: 7:30 am – 4:30 pm

 

To Register: You may register online by Thursday, October 15, 2009 at www.imedex.com, by calling Imedex at +1 (678) 242 0906 or by returning the registration form in this announcement by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment: To pre-register, registration and payment must be received no later than Thursday, October 15, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. An attendee is not registered until full payment is received.

Registration Fee Inclusions: include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at Imedex no later than Thursday, October 15, 2009. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after October 15, 2009.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

The Waldorf=Astoria
301 Park Avenue
New York, New York 10022
Tel.: +1 (212) 355 3000
Fax: +1 (212) 872 7272
Reservation: (877) 476 8792
www.waldorf.com

As one of the first “grand hotels” to combine luxurious elegance with a myriad of amenities and services, the Waldorf=Astoria has been world renowned for over a century. With a reputation for unparalleled hospitality and service, the Art Deco landmark beckons New Yorkers and visitors alike. Since 1893, The Waldorf=Astoria has epitomized the quintessential luxury hotel experience. Each spacious, individually decorated guest room and suite offers a rewarding union of timeless elegance and up-to-the-moment convenience, luxurious comfort and classic sophistication. The legendary shops of Fifth and Madison Avenues are only minutes away, as are numerous art galleries and specialty shops. The hotel itself is home to some of the world’s most luxurious boutiques.

For the convenience of attendees, a limited number of rooms have been reserved until September 24, 2009 at a discounted rate of $359.00 single/double occupancy, plus tax, currently at 14.25% and a $3.50 per night occupancy tax. This rate is not guaranteed outside the conference dates or after September 24, 2009.

To reserve your room please contact the Waldorf=Astoria reservations department at (877) 476 8792 or visit the hotel’s website at www.waldorf.com. To receive the group rate, callers must identify themselves as being with the Lymphoma & Myeloma 2009 group. Internet users must enter the Group/Convention Code: LYM. Reservation requests received after September 24, 2009 may not be guaranteed the group rate.

Dear Colleague,

It is our pleasure to invite you to join us at Lymphoma & Myeloma 2009: An International Congress on Hematologic Malignancies. This fall’s Congress, October 22-24, 2009 at The Waldorf=Astoria in New York, New York, promises to be our most exciting and interactive meeting yet!

Since its inception in 2000, this Congress has grown to nearly 800 attendees and has become the premier forum for discussion on the latest advances in lymphoma and myeloma. Using a dynamic approach, featuring clinical controversies, debates, and examinations of current treatment regimens, attendees will receive a thorough understanding of the evolution of thought and therapy of lymphoma and myeloma, as well as any significant developments which may lead to improved results.

Guided by the expertise of the leaders in the fields of molecular biology, pathology, immunology, and translational and clinical research, this Congress will provide for a stimulating and interactive forum for attendees from all relevant medical specialties.

Allowing attendees the benefit of visiting New York City during one of the most beautiful times of year, this Congress will be the perfect chance for you to get away and enjoy a weekend of learning in the capital city of the world.

We cordially welcome you to our fair city and promise to reward you with an exciting, informative Congress!

Sincerely,
Morton Coleman, MD, Chair

John P. Leonard, MD, Co-Chair,
Lymphoma Session

Ruben Niesvizky, MD, Co-Chair,
Myeloma Session

Richard R. Furman, MD, Co-Chair,
Leukemia Session

ORGANIZER

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

PDF Announcement

PDF Announcement

The following companies have provided an educational grant in support of this Congress:

PLATINUM

Celgene

Genentech BioOncology
and Biogen Idec

Millennium
Pharmaceuticals, Inc

 

SILVER

Cephalon

Medimmune

Merck

 

CORPORATE

Allos

Glaxo Smith Kline

 

AWARDS SUPPORT

Allos Therapeutics, Inc.

 

Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.

 

This program is presented by Genentech BioOncology and is not affiliated with the Lymphoma & Myeloma conference. This is not an independent educational program, and no CME credits will be provided.

 

October 24, 2009
New York, New York
The Waldorf=Astoria

12:45 pm - 2 pm

 

Presented by:

Leo Gordon, MD
Professor, Division of Hematology/Oncology
Northwestern University School of Medicine
Chicago, Illinois

 

Corporate Support

Genentech

 

Genentech BioOncology is excited to sponsor a unique program that provides a concise synopsis of fundamental and evolving concepts on key biological pathways impacting carcinogenesis with a special focus on hematology.

This program, carefully developed with guidance from top translational oncologists, will refresh your understanding of the molecular mechanisms on which current and emerging targeted therapies in the treatment of hematologic malignancies are based. If you are a physician involved in the multimodal treatment of cancer, this program is for you!

 

This presentation includes:

  • - An overview of molecular and cancer biology
  • - Discussion of the cellular properties thatimpact tumorogenesis in hematologicmalignancies
  • - Specific information on signaling pathways that are critical in hematologic malignancies in cancer biology
  • - Current and emerging pathways that may be avenues to explore in the development of anticancer strategies specific to hematology
  • - Key scientific information presented in a context that is relevant to clinicians who treat hematologic malignancies

 

Agenda

12:30 pm
Registration

1:00 pm
Welcome and Introduction

1:10 pm
Presentation and Breakfast

2:00 pm
Question and Answer Session

2:15 pm
Conclusion

How I Manage the Difficult Situations in Hematologic Malignancies

October 23, 2009
New York, New York
The Waldorf=Astoria

 

Corporate Support

Celgene

 

Continuing Medical Education

ACCME

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity has been approved for AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

 

Target Audience

This educational activity is specifically designed for hematologists, medical oncologists and other physicians, clinicians, physicians-in-training, and healthcare professionals (nurses, pharmacists) involved in and/or interested in the therapeutic management of patients with diffuse large B-cell lymphoma, multiple myeloma, or chronic lymphocytic leukemia.

 

Objectives

After successful completion of this activity, participants should be able to:

  • Recommend appropriate medical intervention according to patient treatment history and biology of the disease
  • Discuss clinical prognostic markers available for MM and their relevance in treatment planning
  • Discuss optimal therapeutic strategies for patients with relapsed DLBCL, CLL, and MM that will lead to optimal treatment selection and improved patient outcomes
  • Comment on the salient clinical trial data and clinical utility of emerging therapies for MM, DLBCL, and CLL and their place in the armamentarium of the community oncologist

 

Scientific Agenda

12:15 pm
Introduction and Welcome
David Vesole, MD
Loyola University Health System
Chicago, Illnois

12:20 pm
The post-ASCT patient with relapse Multiple Myeloma – re-evaluating the clinical status and planning a therapeutic approach
David Vesole, MD

12:40 pm
The elderly patient with Multiple Myeloma – utilizing all of the available clinical and biologic prognostic markers to design a long term treatment plan
David Vesole, MD

1:00 pm
The Diffuse Large B-cell Lymphoma patient relapsing after ASCT: Hope or Hospice?
John Leonard

1:20 pm
The CLL patient with progressive disease only a year after FCR – Is there an algorithm that works for community practice?
Alessandra Ferrajoli, MD
M.D. Anderson Cancer Center
Houston, Texas

1:40 pm
Chair Summary and Take Home Points
David Vesole, MD

1:45 pm
Adjourn

 

Overcoming Challenges in Hematological Malignancies

Friday, October 22, 2009
New York, New York
The Waldorf=Astoria

11:30 am – 1:30 pm
The Starlight Roof, 18th Floor

 

Chair:

Sagar Lonial, MD
Winship Cancer Institute
Emory University
Atlanta, Georgia

 

Faculty:

Christopher Flowers, MD
Winship Cancer Institute
Emory University
Atlanta, Georgia

Stephanie Gregory, MD
Rush University Medical Center
Chicago, Illinois

Steven P. Treon, MD, PhD
Dana-Farber Cancer Institute
Boston, Massachusetts


Symposium Organizer

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
www.imedex.com

 

Corporate Support:

The following company has provided an educational grant in support of this symposium:

Millennium Pharmaceuticals, Inc

Millennium

 

Continuing Medical Education:

ACCME
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity has been approved for 1.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.


Target Audience:

This educational activity is specifically designed for hematologists, medical oncologists, transplant oncologists, radiation oncologists and other physicians, physicians-in-training, and healthcare professionals (nurses, pharmacists) involved and/or interested in lymphoma, myeloma and related plasma cell disorders and their management.

 

Objectives:

After attending this symposium, participants should be able to:

  • Determine the optimal induction therapeutic regimen for myeloma based on patient characteristics including transplant eligibility
  • Determine the optimal induction therapeutic regimen for myeloma based on patient characteristics including transplant eligibility
  • Utilize appropriate prognostic factors to stratify mantle cell lymphoma patients and improve initial therapy

 

Scientific Agenda:

11:30 am
Gathering and Cold Plate Lunch

11:45 am
Introductions and pre session audience survey

11:50 am
Induction therapy for transplant eligible and ineligible patients
Sagar Lonial, MD

12:10 pm
Waldenstrom’s Macroglobulinemia
Steve Treon, MD, PhD

12:30 pm
Therapy for Relapsed Follicular Lymphoma
Stephanie Gregory, MD

12:50 pm
Mantle Cell Lymphoma
Christopher Flowers, MD

1:10 pm
Questions and panel discussion

1:20 pm
Post session audience survey

1:30 pm
Adjourn

 

The following companies are exhibitors at this Congress:

Allos

Binding Site

Cephalon

Celgene

CTI

Genentech BioOncology
and Biogen Idec

Genzyme

Glaxo Smith Kline Oncology

Gloucester

Leukemia Lymphoma Society

Lippincott Williams
&Wilkins

Merck

Millennium
Pharmaceuticals, Inc.

Novartis

Proteolix

Vidacare

Opportunities are available to companies interested in exhibiting at this conference. For more information, please contact Cori Gunter at +1(678) 242 0712 or by email at c.gunter@imedex.com.